Simrit Parmar is a Tenured Associate Professor in the department of Lymphoma and Myeloma at MD Anderson Cancer Center, Houston, Texas. Her basic science research interest is focused on the application of adoptive therapy with allogeneic, cord blood derived regulatory T cells. Specifically, Dr Parmar is examining their therapeutic efficacy in inflammation driven cancers including Multiple Myeloma, T-cell Lymphoma, Inflammatory Bone Marrow Disorders including Myelofibrosis, Aplastic Anemia and Myelodysplasia. Dr Parmar is also studying the application of cord blood T regulatory cells to prevent and treat Graft vs Host Disease as well as the Cytokine Release Syndrome associated with the novel CAR T cell therapies. Based on her laboratory findings, cord blood T regulatory cells are being applied for the treatment of COVID19 ARDS where two critically ill patients have been treated at Johns Hopkins Hospital where both the patients got extubated and are currently alive and well.

Based on the technologies arising from the laboratory investigations of Simrit Parmar, M.D., The University of Texas at MD Anderson Cancer Center and Golden Meditech Holdings Limited, a Hong Kong-based integrated healthcare enterprise have created Cellenkos, Inc., a start-up enterprise focused on umbilical cord blood derived T-regulatory ("T-reg") cellular therapies. Dr Simrit Parmar, serves as the Founder of Cellenkos. Please click here to review institutional conflict of interest management plan.

In addition, Dr Parmar has actively participated in developing the comprehensive Amyloidosis programs. She is also actively involved with the global academic program (GAP) and MD Anderson Cancer Network at MD Anderson Cancer Center and expanding the sister institution network, where she serves as part of the Steering Committee. Dr. Parmar serves on the radiation injury treatment network (RITN).

Dr. Parmar enjoys her family time with her husband and 3 children and enjoys traveling.